propafenone has been researched along with triiodothyronine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Carlsson, B; Drvota, V; Häggblad, J; Sylvén, C | 1 |
1 review(s) available for propafenone and triiodothyronine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for propafenone and triiodothyronine
| Article | Year |
|---|---|
Amiodarone is a dose-dependent noncompetitive and competitive inhibitor of T3 binding to thyroid hormone receptor subtype beta 1, whereas disopyramide, lignocaine, propafenone, metoprolol, dl-sotalol, and verapamil have no inhibitory effect.
Topics: Amiodarone; Anti-Arrhythmia Agents; Binding, Competitive; Disopyramide; Dose-Response Relationship, Drug; Humans; Lidocaine; Metoprolol; Propafenone; Receptors, Thyroid Hormone; Sotalol; Triiodothyronine; Verapamil | 1995 |